Jun 25, 2026 07:40AM
Jun 16, 2026 04:30PM
Jun 16, 2026 04:30PM
Jun 4, 2026 10:09AM
Jun 4, 2026 10:09AM
Jun 2, 2026 07:01AM
Jun 2, 2026 07:01AM Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
May 27, 2026 04:05PM
May 27, 2026 04:05PM
May 4, 2026 04:01PM
Apr 24, 2026 06:45AM
Apr 14, 2026 07:08AM
Apr 14, 2026 07:00AM
Apr 14, 2026 07:00AM Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Apr 14, 2026 06:47AM
Apr 13, 2026 06:16PM
Apr 13, 2026 06:16PM
Feb 19, 2026 04:01PM
Jan 16, 2026 01:20PM
Jan 14, 2026 06:48AM
Jan 13, 2026 01:24PM FDA extends review of Travere's FILSPARI application for FSGS to 2026
Jan 13, 2026 01:24PM
Jan 13, 2026 07:27AM
Jan 13, 2026 04:57AM
Jan 12, 2026 05:00PM
Jan 12, 2026 05:00PM
Dec 24, 2025 11:54AM
Nov 6, 2025 11:00AM Travere presents late-breaking FILSPARI data at nephrology meeting
Nov 6, 2025 11:00AM
Oct 30, 2025 04:01PM
Oct 17, 2025 09:01AM
Sep 26, 2025 07:02AM
Sep 26, 2025 07:00AM
Sep 11, 2025 06:48AM
Sep 10, 2025 10:30AM Jefferies on Travere Therapeutics (TVTX): 'AdCom Cancellation Clear Positive In Our View Setting Stage For Likely Approval'
Sep 10, 2025 10:11AM
Sep 10, 2025 09:58AM
Sep 10, 2025 07:01AM
Sep 10, 2025 07:01AM
Sep 3, 2025 07:01AM
Aug 28, 2025 07:33AM
Aug 27, 2025 05:09PM FDA approves simplified monitoring for Travere's FILSPARI kidney drug
Aug 27, 2025 05:09PM
Aug 6, 2025 04:01PM
Jul 6, 2025 10:00AM
Jul 1, 2025 10:00AM
Jun 28, 2025 10:00AM
Jun 23, 2025 11:55AM
Jun 18, 2025 12:13PM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
Jun 15, 2025 10:00AM

325,446 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All